Genetic, Biomarker and Biospecimen Core

项目摘要-遗传学、生物标记物和生物质谱学核心(GBBC) 印第安纳州阿尔茨海默病研究中心(IADRC)在创新方面有很强的历史 在分子和成像基因组学方面的研究，并将继续专注于遗传学的作用 和其他类型的生物标记物在更广泛的人群中预测临床轨迹 阿尔茨海默病(AD)和其他痴呆症患者以及临床前期患者 和前驱阶段，如主观认知能力下降(SCI)和轻度认知障碍 (MCI)。遗传学、生物标记物和生物谱系核心(GBBC)在 通过收集统一的生物标本来支持这一总体重点，协调 基因数据和血液生物标记物的产生。GBBC还支持多个 通过广泛共享标本和数据，开展国家努力。 GBBC利用印第安纳州独特的患者群体和基因组资源 大学医学院支持IADRC的每个核心以及总体目标。 GBBC通过对来自以下方面的样本的共同存储来促进新的研究方向 不同的研究小组。然后可以使用这些样本来解决以下研究问题 是IADRC利益的核心。此外，这些样本还可用于 协作性研究，从而增强了所有ADRC关于疾病的研究的力量 易感性、发病和进展。 在这项应用中，GBBC将扩大其范围，通过 定向开发诱导多能干细胞(IPSCs)。英国皇家银行将利用这两项 IUSM-JAX-PITT模型-AD中心，其目标是开发、表征和测试 阿尔茨海默病小鼠模型的治疗策略和IUSM-普渡治疗AD中心，其 目标是整合尖端能力用于早期药物发现，为更广泛的 研究AD靶点假说(Beyond Aβ)以产生新的潜在疗法类别。 IADRC GBBC提出了以下具体目标： 1.从临床核心中看到的所有受试者获得纵向生物样品，并 支持地方和国家的研究。 2.获得生物标志物数据，以支持正在进行的认知障碍和痴呆症研究。 3.从选定的IADRC参与者中建立IPSC，以支持当地的研究。 4.提供遗传学和生物标记物领域的教育。

Project Summary – Genetics, Biomarker, and Biospecimen Core (GBBC) The Indiana Alzheimer’s Disease Research Center (IADRC) has a strong history of innovative research in molecular and imaging genomics and will continue to focus on the role of genetics and other types of biomarkers as predictors of clinical trajectories among the broader group of individuals with Alzheimer’s disease (AD) and other dementias, as well as those in preclinical and prodromal stages, such as subjective cognitive decline (SCI) and mild cognitive impairment (MCI). The Genetics, Biomarker and Biospecimen Core (GBBC) plays a central role in supporting this overall focus through the collection of uniform biospecimens, coordination of genetic data and generation of blood-based biomarkers. The GBBC also supports multiple national efforts through the broad sharing of specimens and data. The GBBC leverages the unique patient populations and genomics resources at Indiana University School of Medicine to support each Core as well as the overall goals of the IADRC. The GBBC fosters new research directions through the common banking of samples from diverse research groups. These samples are then available to address research questions that are central to the interests of the IADRC. In addition, these samples are available for collaborative studies, thereby enhancing the power of all ADRC studies focused on disease susceptibility, onset and progression. In this application, the GBBC will expand its scope to also support functional studies through the targeted development of induced pluripotent stem cells (iPSCs). The GBBC will leverage both the IUSM-JAX-Pitt MODEL-AD Center, whose goal is to develop, characterize and test therapeutic strategies in mouse models of AD and the IUSM-Purdue TREAT AD Center, whose goal is to integrate sophisticated capabilities for early drug discovery, to contribute to a broader study of AD target hypotheses (beyond Aβ) to generate new classes of potential therapeutics. The IADRC GBBC proposes the following specific aims: 1. Obtain longitudinal biospecimen samples from all subjects seen in the Clinical Core and support local and national research studies. 2. Obtain biomarker data to support ongoing studies of cognitive impairment and dementia. 3. Establish iPSCs from select IADRC participants to support local research studies. 4. Provide education in the areas of genetics and biomarkers.